Table 3.
Comparison of clinicopathological characteristics between the FNR and accuracy rate for SLNB.
| Characteristic | n | FNR (%) | n | Accuracy rate (%) | χ2 | P |
|---|---|---|---|---|---|---|
| Age, years | 0.000 | 1.000 | ||||
| ≤40 | 1 | 8.33 | 32 | 96.97 | ||
| >40 | 15 | 10.56 | 311 | 95.40 | ||
| Menstruation status | 0.288 | 0.591 | ||||
| Premenopause | 5 | 8.62 | 130 | 96.30 | ||
| Postmenopause | 11 | 11.46 | 213 | 95.09 | ||
| Body mass index (kg/m2) | 0.000 | 1.000 | ||||
| <30 | 14 | 10.00 | 307 | 95.64 | ||
| ≥30 | 2 | 14.29 | 36 | 94.74 | ||
| Tumor location | 0.436 | 0.509 | ||||
| Outer upper quadrant | 9 | 10.98 | 164 | 94.80 | ||
| Other | 7 | 9.72 | 179 | 96.24 | ||
| Side of the tumor | 1.217 | 0.270 | ||||
| Left | 6 | 7.32 | 177 | 96.72 | ||
| Right | 10 | 13.9 | 166 | 94.5 | ||
| Pathological type | – | 0.325* | ||||
| IDC | 14 | 10.00 | 319 | 95.80 | ||
| ILC | 1 | 16.67 | 13 | 92.86 | ||
| Other | 1 | 12.50 | 11 | 91.67 | ||
| Tumor size (mm) | 3.913 | 0.048 | ||||
| ≤20 | 14 | 16.87 | 217 | 93.94 | ||
| >20 | 2 | 2.82 | 126 | 98.44 | ||
| Estrogen receptor | 0.076 | 0.782 | ||||
| Negative | 3 | 11.11 | 86 | 96.63 | ||
| Positive | 13 | 10.24 | 257 | 95.19 | ||
| Progesterone receptor | 0.789 | 0.375 | ||||
| Negative | 4 | 10.00 | 123 | 96.85 | ||
| Positive | 12 | 10.53 | 220 | 94.83 | ||
| Ki-67 expression levels | 0.530 | 0.467 | ||||
| <14% | 1 | 3.26 | 56 | 98.25 | ||
| ≥14% | 15 | 12.19 | 287 | 95.03 | ||
| HER2 state | 0.722 | 0.395 | ||||
| Positive | 8 | 10.26 | 135 | 94.41 | ||
| Negative | 8 | 10.53 | 208 | 96.29 | ||
| Histological grade | 0.772 | 0.680 | ||||
| I | 1 | 5.26 | 45 | 97.82 | ||
| II | 12 | 11.88 | 237 | 95.18 | ||
| III | 3 | 8.82 | 61 | 95.31 | ||
| Lymphovascular invasion | 1.426 | 0.232 | ||||
| Present | 3 | 15.79 | 25 | 89.29 | ||
| Absent | 13 | 9.5 | 318 | 96.07 | ||
| Multifocality | – | 0.589* | ||||
| Multifocal | 1 | 9.09 | 18 | 94.74 | ||
| Unifocal | 15 | 10.34 | 325 | 95.59 | ||
| Molecular subtypes | 5.095 | 0.165 | ||||
| Luminal A | 1 | 4.17 | 48 | 97.95 | ||
| Luminal B | 12 | 11.88 | 208 | 94.55 | ||
| HER2 positive | 3 | 17.65 | 48 | 94.12 | ||
| Triple negative | 0 | 0 | 39 | 100 | ||
| Number of dissected SLNs | 13.048 | 0.005 | ||||
| 1 | 8 | 23.53 | 72 | 90.00 | ||
| 2 | 6 | 15.79 | 82 | 93.18 | ||
| 3 | 1 | 3.85 | 61 | 98.39 | ||
| ≥ 4 | 1 | 1.79 | 128 | 99.22 | ||
| Number of metastatic lymph nodes | – | 0.001* | ||||
| ≤3 | 10 | 8.26 | 316 | 96.93 | ||
| ≥ 4 and ≤9 | 6 | 25.0 | 19 | 76.0 | ||
| ≥10 | 0 | 0 | 8 | 100 |
*Fisher’s exact test. FNR, false negative rate; SLNB, sentinel lymph node biopsy; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor 2; SLNs, sentinel lymph nodes.